Curocell

Curocell EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curocell (372320.KQ) as of Oct 27, 2026 is -36.29 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -30.24 B KRW — a change of 20.01% (lower).

EBITDA

-36.29 BKRW

YoY

20.01%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curocell is 2025 -36.29 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curocell was 2024 -30.24 B KRW. It decreases by 20.01% lower compared to the previous year.

The Curocell EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2021
-13.57 B KRW
Jan 1, 2022
-19.60 B KRW
Jan 1, 2023
-26.42 B KRW
Jan 1, 2024
-30.24 B KRW
Jan 1, 2025
-36.29 B KRW
The Curocell EBITDA history
YEAREBITDAYoY
-36.29 BKRW+20.01%
-30.24 BKRW+14.43%
-26.42 BKRW+34.83%
-19.60 BKRW+44.40%
-13.57 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curocell is -36.29 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Curocell changed from -30.24 B KRW to -36.29 B KRW, representing a 20.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Curocell since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Curocell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Curocell

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Curocell